Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation.

@article{Kastrukoff1991SystemicLI,
  title={Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation.},
  author={Lorne F Kastrukoff and Joel J F Oger and Wallace W. Tourtellotte and Stephen L. Sacks and Jared Berkowitz and Donald W. Paty},
  journal={Neurology},
  year={1991},
  volume={41 12},
  pages={
          1936-41
        }
}
Immunologic functions are studied in conjunction with a placebo-controlled trial of lymphoblastoid interferon (IFN) in patients with chronic progressive (CP) multiple sclerosis. Prior to treatment, CD4+ cells are significantly increased and CD8+ cells decreased in the blood of MS patients. Both CD5+ and CD4+ cells increase significantly with IFN therapy early during the treatment phase of the trial, while the number of CD8+ cells decreases steadily, becoming significant at 6 months. CNS IgG… CONTINUE READING
Highly Cited
This paper has 18 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations